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Intercellular adhesion molecule-1 (ICAM-1) in cerebral vascular endothelium induced by ischemic insult triggers leukocyte
inﬁltration and inﬂammatory reaction. We investigated the mechanism of hypothermic suppression of ICAM-1 in a model of
focal cerebral ischemia. Rats underwent 2 hours of middle cerebral artery occlusion and were kept at 37
◦Co r3 3
◦C during
occlusion and rewarmed to normal temperature immediately after reperfusion. Under hypothermic condition, robust activation
of extracellular signal-regulated kinase-1/2 (ERK1/2) was observed in vascular endothelium of ischemic brain. Hypothermic
suppression of ICAM-1 was reversed by ERK1/2 inhibition. Phosphorylation of signal transducer and activator of transcription 3
(STAT3) in ischemic vessel was attenuated by hypothermia. STAT3 inhibitor suppressed ICAM-1 production induced by stroke.
ERK1/2 inhibition enhanced phosphorylation and DNA binding activity of STAT3 in hypothermic condition. In this study, we
demonstrated that hypothermic suppression of ICAM-1 induction is mediated by enhanced ERK1/2 activation and subsequent
attenuation of STAT3 action.
1.Introduction
Intercellular adhesion molecule-1 (ICAM-1) is a member of
the immunoglobulin superfamily and the principal ligand
forleukocytefunction-associatedantigen-1(LFA-1),amem-
ber of the integrin superfamily. ICAM-1/LFA-1 adhesion
system assists leukocyte movement into the tissue. LFA-1-
positiveleukocytesareinducedtoadheretoICAM-1-positive
endothelial surface [1, 2], and then to pass through the
basement membrane into the tissue [3, 4]. Many animal and
human studies indicate that ICAM-1 is implicated in the
pathogenesis of ischemic cardiovascular and cerebrovascular
disorders [5–8]. Especially during reperfusion period of
stroke, inﬁltrated leukocytes contribute to the secondary
injury by producing toxic substances that damage the brain
cells and disrupt the blood-brain barrier [9, 10]. Since
ICAM-1 is an important factor of leukocyte inﬁltration
and reperfusion injury in stroke, intervention of ICAM-1
induction has been a promising therapeutic strategy against
stroke.
The remarkable beneﬁt of mild hypothermia in brain
ischemia has long been recognized and remains one of
the most powerful neuroprotective strategies in cerebral
ischemia both experimentally and clinically [11]. Many
studies indicate that inﬂammatory response contributes
signiﬁcantly to the secondary injury after ischemia [12, 13],2 Stroke Research and Treatment
and protection by mild hypothermia is associated with
anti-inﬂammatory processes [14–16]. Even though there is
considerable interest in the potential therapeutic role of
induced hypothermia, the molecular basis of hypothermic
protection remains mostly unknown.
Previously, we and others have demonstrated that
hypothermia attenuated ICAM-1 induction [17–21]a n d
neutrophil inﬁltration after stroke attack [15, 16, 22]. In
most studies, hypothermia was applied during ischemic or
few hours after ischemia. Therefore, there is a time gap
between hypothermia application and ICAM-1 induction
when the temperature was already returned to normal body
temperature. Since hypothermia is known to interfere with
some ischemia related signaling pathways and gene expres-
sion [23, 24], we hypothesize that hypothermia applied
during ischemia interferes the upstream pathway of ICAM-1
expression and investigated the molecular mechanism in the
vascular endothelium of the ischemic brain.
2.MaterialsandMethods
2.1. Animal Model. Experiments were carried out according
to the guidelines for the animal care and use of laboratory
animal protocols approved by our university administrative
panel on laboratory animal care. Rats were housed with
food and water available ad libitum under diurnal lighting
conditions and temperature-controlled environment until
the day of experiment.
2.2. Focal Cerebral Ischemia by Transient Middle Cere-
bral Artery Occlusion (MCAO). Male Sprague-Dawley rats
weighing 290 to 320g were anesthetized with enﬂurane
and maintained during surgical procedures. Physiological
parameters were monitored and maintained in the normal
range as shown previously [14]. Ischemia was induced
using an occluding intraluminal suture. An uncoated 30mm
long segment of 3–0 nylon monoﬁlament suture with the
tip rounded by ﬂame was inserted into the stump of the
common carotid artery and advanced into the internal
carotid artery approximately 19-20mm from the bifurcation
inordertooccludetheostiumofmiddlecerebralartery.After
2 hours of ischemic period, the suture was removed and the
animal was allowed to recover. Sham-operated animals were
treated in the same manner as the ischemic animals, but
no ischemia was applied. During surgery, rectal temperature
was maintained between 37-38◦C. Mild hypothermia (33◦C
of rectal temperature) was achieved as previously described
usingparadigmsassociatedwithneuroprotection[14].Cool-
ing began upon ischemia onset, maintained for 2 hours and
terminated immediately after reperfusion. To inhibit ERK1/2
activation, U0126 (0.5mg/kg, Cell Signaling Technology)
was administered via tail vein 30 minutes before MCAO.
Cucurbitacin I or JSI-124 (0.1mg/kg; selective JAK/STAT
inhibitor, Calbiochem) was injected intraperitoneally 1 hour
before MCAO.
2.3. Brain Endothelial Cell Culture and Oxygen Glucose Depri-
vation (OGD) Study. bEnd.3 cells, mouse brain endothelial
cell line was purchased from American Type Culture Collec-
tion (Rockville, MD). The cells were cultured with DMEM
containing 10% FBS at 37◦C in a humidiﬁed 5% CO2
incubator. JSI-124 (10μM) or U0126 (10μM) was treated
30min before OGD. OGD was performed by transferring
cells to an anaerobic chamber (Forma) with an atmosphere
of 5% CO2,5 %H 2, and 90% N2. The culture medium was
replaced three times with deoxygenated PBS and serum free
media for OGD. Cultures were placed in a humidiﬁed 37◦C
or 33◦C incubator within the anaerobic chamber for 4hr.
Oxygen tension was monitored with an oxygen electrode
meter and was kept under 0.02%. OGD was ended by adding
5.5mMglucosetotheculturemedium,andthecultureswere
returned to the normoxic (37◦C) or hypothermic (33◦C)
incubator (reperfusion). The cultured cells and media were
harvested for further study.
2.4. Tissue Preparation and Infarct Area Measurement. Rats
were euthanized by carbon dioxide overdose and perfused
with cold normal saline immediately. The brain was quickly
removed and sectioned into 2mm thick slices starting at the
frontal pole using a brain matrix slicer. Some slices were
immersed in 2% 2,3,5-triphenyl tetrazolium chloride (TTC,
Sigma)andincubatedat37◦Cfor20minutes.Toassesslesion
area, TTC-stained slices were photographed and analyzed by
Image-Janalysissoftware(publicdomainsoftwaredeveloped
at NIH, available at http://rsb.info.nih.gov/ij/). Lesion area
was determined as the percentage of the total ipsilateral
hemispheric area. Other slices were processed for further
studies.
2.5. Immunohistochemistry. From paraﬃne m b e d d e db r a i n
slices, 6 μm thick sections were cut. After deparaﬃnization,
sections were treated with 0.03% H2O2 and blocked in 1%
bovine serum albumin and 5% normal serum. Following
incubation with primary antibodies against ICAM-1 (1:100,
Serotec), phosphorylated ERK1/2 (1:200, Santa Cruz), total
ERK1/2 (1:200, Santa Cruz), STAT3 phosphorylated at
Ser727 (1:200, Cell Signaling), and total STAT3 (1:200,
Santa Cruz), respectively, biotin-labeled anti-IgG secondary
antibody (1:200, Vector Labs) was treated. Antibodies were
detected using the Vector ABC kit (Elite Vectastain ABC kit,
Vector Labs) and colorized with 0.05% diaminobenzidine
(DAB, Vector Labs). Negative controls were run in parallel
using adjacent sections incubated with IgG instead of the
primaryantibody.Forﬂuorescencestaining,weusedFITCor
Cy3-labeled anti-IgG secondary antibody (1:200, Jackson)
instead of biotin-labeled antibody.
2.6. Western Blot Analysis. Brain samples were homogenized
in Laemmli’s lysis buﬀer plus protease inhibitors. Aliquots
containing 30μg of protein were subjected to 10% SDS-
PAGE. Protein bands were transferred to polyvinylidene
diﬂuoride membrane (Millipore), probed by incubating
with the primary antibodies, and followed by a horseradish
peroxidase conjugated secondary antibody (1:2000, Santa
Cruz). We used the following primary antibodies raised
against ICAM-1 (1:500, Serotec), phosphorylated ERK1/2Stroke Research and Treatment 3
(1:1000, Santa Cruz), total ERK1/2 (1:1000, Santa Cruz),
phosphorylated STAT3 (1:1000, Cell Signaling), and total
STAT3 (1:1000, Santa Cruz). To determine the speciﬁcity
of the primary antibodies, we used antibodies preabsorbed
with blocking peptides instead of primary antibodies. Blots
werevisualized using theECL system(Amersham)according
to the manufacturer’s directions, and exposed to X-ray ﬁlm.
Equal protein loading was conﬁrmed by measuring β-actin
(1:5000, anti β-actin, Sigma). Densitometric measurements
were made from the ﬁlm using a GS-700 imaging densito-
meter (Bio-Rad), then quantiﬁed using Multi-Analyst (Bio-
Rad). For quantiﬁcation of relative protein expression, the
opticaldensityoftheproteinbandofinterestwasnormalized
to the optical density of β-actin on the same gel.
2.7. Microwell Colorimetric STAT3 DNA Binding Assay. The
binding ability of STAT3 to its DNA consensus sequences
was measured using a commercially available kit (Trans-
AMTMSTAT3,ActiveMotif).Inthisassay,tissuelysateswere
isolated from the brain tissue and tested for their ability to
bind to a double-stranded oligonucleotide probe containing
the consensus binding sequence for STAT3. Samples were
homogenized in 3mL ice-cold lysis buﬀer (20mmol/L
HEPES, pH 7.5; 350mmol/L NaCl; 20% glycerol; 1% Igepal-
CA630; 1mmol/L MgCl2; 0.5mmol/L EDTA; 0.1mmol/L
EGTA) per gram tissue. Lysates were centrifuged at 10,000g
for 10 minutes at 4◦C. The supernatant was used to measure
the protein content by a Bradford-based assay (Bio-Rad).
STAT3 activity was determined by the sample’s ability to
bindtoconsensussequences(5 -GGGACTTTCC-3 )ina96-
well plate. A primary antibody that recognizes an epitope
on STAT3 and is accessible only when STAT3 is activated
and bound to its target DNA was added to the wells,
followed by a secondary horseradish peroxidase-conjugated
antibody. Developing solution (tetramethylbenzidine) was
added and the colorimetric reaction was stopped by adding
stopsolution(0.5mol/LH2SO4).Afterstoppingthereaction,
absorbance was measured on a spectrophotometer within 5
minutes at 450nm with a reference wavelength of 625nm.
HeLa whole-cell extract was used as positive control. The
STAT3 wild-type and mutated consensus oligonucleotides
were used in order to monitor the speciﬁcity of the assay.
2.8. Statistical Analysis. Data are given as means ± SEM.
Comparisons between groups were performed using stan-
dard statistical methods using SigmaStat (SPSS). The data
were analyzed by one-way ANOVA, Kruskal-Wallis one-way
ANOVA on ranks, or unpaired t-test. Statistical signiﬁcance
was determined at the P<. 05 level.
3. Results
3.1. Hypothermia Potentiated ERK1/2 Phosphorylation in the
Vascular Endothelium of the Ischemic Brain. We observed
the presence of phosphorylated or activated ERK1/2 in the
ischemic brain using immunohistochemistry (Figure 1(a))
and demonstrated its localization in the endothelium using
ﬂuorescence double-labeling with antibody against CD31,
an endothelial cell marker from the brain tissue at 2 hours
after MCAO (Figure 1(b)). To ﬁnd out the evidence that
ERK1/2 pathway in the endothelium is related with ICAM-1
induction, we ﬁrst investigated the eﬀect of hypothermia on
the activation of ERK1/2. From the immunohistochemistry
study, the number and intensity of phosphorylated ERK1/2
immunoreactivity were higher in hypothermia group than
normothermia (Figure 1(a)). To obtain quantitative data, we
performedWesternblotanalysisandobservedthatischemia-
induced phosphorylated ERK1/2 level was signiﬁcantly
higher in hypothermia group than normothermia while
total ERK1/2 was not aﬀected by the temperature diﬀerence
(Figure 2(a)).
3.2. ERK1/2 Inhibitor Reversed Hypothermic Suppression
of ICAM-1. To demonstrate the role of ERK1/2 in the
hypothermic attenuation of ICAM-1 induction, we adminis-
tered U0126, a MEK inhibitor suppressing phosphorylation
of ERK1/2, to the animals and measured the ICAM-1 level in
theischemicbrain.TheoptimaldoseofU0126wasevaluated
in the pilot study, and activation of ERK1/2 in brain was
almost completely suppressed when U0126 (0.5mg/kg) was
administered 30 minutes before MCAO onset (Figure 2(b)).
InU0126untreatedanimals,ICAM-1inductionwasreduced
by hypothermia. But after U0126 treatment, ICAM-1 induc-
tion was not suppressed by hypothermia (Figure 2(b)).
3.3. STAT3 Phosphorylation Was Induced by Ischemia and
Attenuated by Hypothermia. Even though hyperactivation
of ERK1/2 seems to suppress ICAM-1 induction, the
association between ERK1/2 phosphorylation and ICAM-
1 expression is not clearly reported. So we ﬁrst investigate
the signal pathways implicated in the regulation of ICAM-
1 expression in our model. During ischemia and until few
hours after reperfusion initiation, phosphorylated STAT3
was observed in the ischemic brain, especially in the vessels
(Figure 3(a)). At 24 hours after ischemia, STAT3 was not
observed in the vessels. Western blot analysis demonstrated
that ischemia increased STAT3 phosphorylation at 2 and 6
hours and it was declined to the basal level at 24 hours.
Hypothermic attenuation of STAT3 phosphorylation was
observedbothinimmunohistochemicallystainedtissuesand
Western blotted gel images (Figures 3(a) and 3(b)).
3.4. STAT3 Inhibitor Attenuated ICAM-1 Induction. The
presenceofphosphorylatedSTAT3,whichactsasatranscrip-
tion factor, in the vessels and its suppression by hypothermia
imply that STAT3 is important in ICAM-1 expression. To
get more evidence of STAT3’s role in ICAM-1 induction, we
treatedanimalswithJSI-124,aninhibitorofSTAT3,at1hour
before MCAO. The protein level of ICAM-1 was compared
between the STAT3 inhibitor-treated and vehicle-treated
groups. ICAM-1 induction at 24 hours after ischemia was
signiﬁcantly inhibited by JSI-124 treatment (Figure 3(c)).
3.5. ERK1/2 Inhibition Enhanced STAT3 Phosphorylation and
DNA Binding Activity. Based on the data so far, it seems that4 Stroke Research and Treatment
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Figure 1: Photomicrographs of the cerebral cortex in the ischemic brain with immunohistochemical staining for phosphorylated ERK1/2.
(a) Phosphorylated ERK1/2 is detected in the ischemic brain under normothermic (37) or hypothermic (33) condition but not in the
nonischemic control brain (sham) at 2 hours after MCAO initiation. The number and intensity of ERK1/2 immunoreactive vessels were
higher in hypothermic group. (b) Fluorescence double labeling illustrates the colocalization of CD31 (red), an endothelial marker, and
phosphorylated ERK1/2 (green) in the vessels of the hypothermia group at 2 hours after MCAO initiation. Scale bar: 100μm.
enhanced ERK1/2 activation and reduced STAT3 activation
are the key role players of hypothermic suppression of
ICAM-1 induction. To investigate whether these two factors
are working dependently or not, we treated U0126 and
observed phosphorylation and DNA binding activity of
STAT3. Under hypothermic condition, STAT3 activation at
2 hours after MCAO was reduced. But when U0126 was
treated to the hypothermic group, phosphorylated STAT3
was increased to the level of normothermia condition
(Figure 4(a)). Since activity of STAT3 as a transcription
factor can be indirectly estimated using the binding ability
of STAT3 to its consensus sequence in the promoter area,
we measured DNA binding activity of STAT3 as well.
Tissue lysates from ischemic brain tissue of the hypothermia
group were taken from the animals treated with or without
ERK1/2 inhibition. U0126 treatment signiﬁcantly enhanced
the binding activity of STAT3 (Figure 4(b)).
4. Discussion
This study is designed to investigate the mechanism of
hypothermic suppression of ICAM-1 induction following
brainischemia.Ourdataaresummarizedasfollows.ICAM-1
induction is suppressed by hypothermia after stroke. Stroke
activates ERK1/2 mildly under normothermic condition
and hypothermia potentiates ERK1/2 activation robustly.
Stroke activates STAT3 under normothermic group and
hypothermia attenuates this. ERK1/2 inhibition increases
STAT3 activation and attenuates hypothermic eﬀect. STAT3
inhibitor attenuates ICAM-1 induction. Based on these
results, we suggest that hypothermia enhances ERK1/2
activation, inhibits STAT3 activation, and then leads to
suppression of ICAM-1 induction.
Our ﬁrst ﬁnding is potentiation of ERK1/2 activation
by hypothermia. Even though it is well accepted that
most of the metabolic and enzymatic pathways are down-
regulated by hypothermia, increased activity of ERK1/2
by hypothermia was reported by many studies [25–29].
Since phosphorylated ERK1/2 from the brain tissue is a
sum from mixed cell types, it cannot clearly indicate pure
endothelial component. Our in vitro work (Supplemen-
tary Figure 2 available online at doi:10.4061/2011/846716)
which demonstrated hypothermic enhancement of ERK1/2
activation in cultured mouse brain endothelial cells after
oxygen-glucose deprivation should be a strong support for
the hypothermic eﬀect in the brain vascular endothelium.
Roberts and colleagues also reported hypothermic activationStroke Research and Treatment 5
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Figure 2: Western blot analysis of phosphorylated ERK1/2 and ICAM-1. (a) Phosphorylation of ERK1/2 was signiﬁcantly higher in
hypothermic(33)brainsthannormothermic(37)onesat15,30, and120 minutesafter ischemicinsult(n = 6pergroup).TotalERK1/2level
was not changed. (b) Ischemia-induced increase of ICAM-1 at 24 hours after MCAO was suppressed by hypothermia. But this suppression
wasnotobservedwhenERK1/2inhibitionwasdone(U0126,n = 4)atthedosewhichalmostcompletelyinhibitedERK1/2phosphorylation.
∗P<. 05 versus normothermia.
of ERK1/2 in endothelial cells [30]. When hypothermia
was applied without ischemic stimuli, it was not strong
enough to activate ERK1/2. There was no diﬀerence between
normothermia and hypothermia in nonischemic brain.
Cultured brain endothelial cells showed the same result
(Supplementary Figure 1). Even though we do not have a
clear idea, it seems that hypothermia potentiates ERK1/2
activation when ERK1/2 activation is triggered ﬁrst by
ischemia. Hypothermia may have a direct inﬂuence on
ERK1/2 itself or can aﬀect one of the upstream factors of
ERK1/2 pathway. Even though we did not investigate the
upstream factors, we can draw valuable clues from 3 reports
[25, 28, 29]. Chan and colleagues showed that hypothermic
stress leads to activation of Ras in rat ﬁbroblasts, and Raf-
Mek-ERK cascade is rapidly activated when hypothermic
cells are returned to physiologic temperature [28]. Sakurai
and colleagues reported that mild hypothermia protects
cells from TNF-alpha-induced apoptosis, at least partly, via
induction of cold-inducible RNA-binding protein (CIRP),
and that CIRP protects cells by activating the ERK pathway
[25]. At our hands, CIRP gene expression was detected
a few hours later than ERK1/2 activation in response to
hypothermia (unpublished data). This implies that CIRP
cannot be in the upstream of ERK1/2 pathway in our model.
Atkins and colleagues demonstrated ERK activation in a
traumatic brain model using similar hypothermia model as
ours [29]. So we speculate that hypothermia acts on Raf-
Mek-ERK cascade. Since the role of p38 or c-Jun N-terminal
kinases (JNK) in the inﬂammation is well known, we also
investigated p38 and JNK activation in the preliminary
experiment. Active form of JNK was not detected in the
vessel at the earlier time period after stroke, and phos-
phorylated p38 was observed in the vessels almost at the
time window of ERK1/2 but showed no diﬀerence between
normothermic and hypothermic conditions (unpublished
data).
To elucidate the transcription factor which might be
down-regulated by hypothermia and ERK1/2 signal, we
searched references on ICAM-1 expression regulatory sys-
tem. Studies on ICAM-1 promoter demonstrated the pres-
enceofSTAT1/3bindingmotifsequence,interferonresponse
element (IRE) [31, 32], activator protein 1 (AP-1), nuclear
factor kappa B (NFkappaB), Ets, CCAAT/enhancer binding
protein (c/EBP), and SP1 [33, 34]. Among these transcrip-
tion factors, we need to ﬁnd the candidate which is the key
factorofICAM-1inductioninourmodel.Inthepreliminary
experiment, we investigated a couple of transcription factors
using immunohistochemistry and Western blot analysis. It
is well known that NFkappaB system is the major pathway
of inﬂammation [35, 36] and our previous study [37] also
demonstrated that hypothermic suppression of NFkappaB
system led to suppression of inﬂammation in stroke. Even
though the role of NFkappaB in ICAM-1 induction was
reported in many studies [38–40], Wen and colleagues [41]
showed that nuclear translocation of NFkappaB observed in
the ischemic area was mostly in the neurons and astrocytes.6 Stroke Research and Treatment
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Figure 3: (a) STAT3 phosphorylation in the cerebral cortex of the ischemic brain. Photomicrograph illustrates the presence of
phosphorylated STAT3 in the vessels of the ischemic brain at 2 hours after ischemic insult. Positive immunoreactivity is not observed in
nonischemic brain (sham), and hypothermia (33) reduced the number of phosphorylated STAT3 positive cell compared with normothermic
group (37). Scale bar: 100μm. (b) Western blot analysis shows that ischemia-induced STAT3 phosphorylation at 2 and 6 hours after MCAO
onset in normothermic brain (37, n = 6) is reduced in hypothermia group (33, n = 6). ∗P<. 05 versus normothermia. (c) Western blot
analysis demonstrates that ICAM-1 induction at 24 hours after MCAO is reduced by STAT3 inhibitor treatment (JSI, n = 4). ∗P<. 05 versus
sham; #P<. 05 versus ischemia without JSI-124.
Our preliminary data also showed no NFkappaB transloca-
tion in the vessels during the early period ahead of ICAM-
1 induction. Therefore, we tried other candidates. During
ischemia and few hours after reperfusion initiation, c-Fos
and phosphorylated STAT3 were observed in the ischemic
brain. Phosphorylated STAT3 localized exclusively in the
vessels while c-Fos were found in vessels and other cell
types as well. When hypothermia was applied, there was
no temperature diﬀerence in c-Fos (data not shown) but
STAT3 phosphorylation was reduced by hypothermia. This
suggests that STAT3 is a temperature sensitive transcription
factor of ICAM-1. Yang and colleagues showed the evidence
of STAT3 as a transcription factor of ICAM-1 in renal
ischemia/reperfusion model [42]. By blocking Janus kinase
(JAK)/STAT signal with selective JAK2 inhibitor tyrphostin
AG490, expression of ICAM-1 was signiﬁcantly inhibited,
renal function was improved, and histological lesions and
apoptosis were reduced [42]. In our stroke model, we also
observed that STAT3 inhibitor JSI-124 eﬀectively reduced
ICAM-1 induction. These data might support that STAT3
plays as a key transcription factor of ICAM-1 expression in
our system.Stroke Research and Treatment 7
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Figure 4: Eﬀect of ERK1/2 inhibition on the STAT3 phosphorylation and DNA binding activity. (a) Western blot analysis demonstrates that
STAT3 activation at 2 hours after ischemic insult is increased in normothermic group (37, n = 6). This increase was reduced by hypothermia
(33, n = 6). In hypothermic group, U0126 treatment (33, n = 4) enhanced STAT3 phosphorylation to the level of normothermia group (37,
n = 6). ∗P<. 05 versus sham; #P<. 05 versus hypothermic ischemia without U0126. (b) DNA binding activity assay of STAT3 using nuclear
fraction from ischemic brain under hypothermia condition shows increased binding activity of STAT3 at 2 hours after MCAO (n = 4).
STAT3 binding was further augmented by U0126 treatment (n = 4). ∗P<. 05 versus sham; #P<. 05 versus ischemia without U0126.
To evaluate whether STAT3 is regulated by ERK1/2 in
addition to hypothermia, we tested the eﬀect of ERK1/2
inhibition. When ERK1/2 activity was reduced, STAT3
phosphorylation and DNA binding activity were enhanced.
Even though ERK1/2’s role as the upstream regulator of
STAT3 can be expected by ERK1/2 inhibition, it is not clear
how ERK1/2 regulates STAT3 pathway. We just speculate that
ERK1/2 might inhibit STAT3 directly or indirectly via one of
the factors located in the upstream of STAT3 pathway. Even
though JSI-124 eﬀectively blocked the ICAM-1 induction,
infarction size was not prevented or reduced in contrast to
our expectation. We assume that there is a reason to explain
this disappointing result. Many investigators have suggested
STAT3signalpathwayasaneuroprotectionmechanism.Shyu
and colleagues [43] showed that secretoneurin’s eﬀect on
reduced cerebral infarction improved motor performance,
and increased brain metabolic activity in MCAO model
was mediated via the JAK2/STAT3 pathway. Yamashita
and colleagues [44] found that endogenous IL-6 plays a
critical role in the neuroprotection, and its role may be
mediated by STAT3 activation. In general it seems that
STAT1 activation is related to cell death, whereas STAT3
activation is often associated with cell survival [45]. We
also observed STAT3 immunoreactivity in neuron at 6
and 24 hours after MCAO while in the vessels at 2 and
6 hours. In spite of the immunohistochemistry data, we
tried to conﬁrm STAT3 phosphorylation in the endothelial
cells. By repeating in vivo experimental conditions in the
cultured brain endothelial cell system, we could demonstrate
the hypothermic eﬀect on STAT3 phosphorylation and
eﬀect of U0126 on STAT3 phosphorylation (Supplementary
Figure 3). Based on these facts, STAT3 might have two
opposite roles, promotion of ICAM-1 induction in the
vessel and protection of cell in the neurons. This can
explain why STAT3 inhibitor is not protective in our
model. Even though STAT3 inhibitor used in this study was
not protective against stroke, the better outcome can be
expected when the endothelium-speciﬁc STAT3 inhibitor is
developed.
5. Conclusions
We demonstrated that mild hypothermia has a robust sup-
pressive eﬀect on induction of ICAM-1 through regulation
of ERK1/2 and STAT3. Even though mild hypothermia has
been shown to have clinical eﬃcacy in some settings, routine
cooling of stroke victims may not always be practical or
feasible. For those cases, ERK1/2 and STAT3 can be the good
target of pharmaceutical treatment.8 Stroke Research and Treatment
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